News FDA probing deaths with DMD gene therapy Elevidys The FDA has launched a formal investigation into two liver failure-related deaths in patients treated with Duchenne gene therapy Elevidys.
News DMD gene therapy Elevidys linked to new liver failure case Another death from liver failure has been seen with Roche and Sarepta's Duchenne muscular dystrophy therapy Elevidys, prompting a pause on treatment.
News Multiple studies of Sarepta's DMD therapy halted after death Three studies of Sarepta's Elevidys Duchenne gene therapy have been placed on hold as the death of a 16-year-old boy is investigated.
News Sarepta slumps on Elevidys patient death The death of a patient treated with Sarepta's Duchenne muscular dystrophy gene therapy Elevidys has hit its share price.
News Sarepta bags key expansion to DMD gene therapy label in US Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD) will be an option for many more patients in the US after the FDA expanded the breadth of its approved labelling.
News Future of Pfizer’s Duchenne gene therapy in doubt Pfizer is “evaluating appropriate next steps” for its Duchenne muscular dystrophy (DMD) gene therapy after it failed a phase 3 trial.
News UK probes link between GLP-1 drugs and pancreatitis The UK is studying cases of pancreatitis in people taking GLP-1 drugs for weight loss or type 2 diabetes to see if genetics may make them vulnerable.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
